

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/785,374
Filing Date	2/24/2004
First Named Inventor	Summar et al.
Art Unit	1634
Examiner Name	Diana B. Johannsen
Attorney Docket Number	1242/58 CIP

Sheet	1	of	8
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	1	US-4,196,265	04-01-1980	Koprowski et al.	
	2	US-4,458,066	07-03-1984	Caruther et al.	
	3	US-4,554,101	11-19-1985	Hopp	
	4	US-4,683,195	07-28-1987	Mullis et al.	
	5	US-4,683,202	07-28-1987	Mullis	
	6	US-4,736,866	04-12-1988	Leder et al.	
	7	US-4,769,331	09-06-1988	Roizman et al.	
	8	US-4,965,188	10-23-1990	Mullis et al.	
	9	US-4,996,236	02-26-1991	Nakamura et al.	
	10	US-5,162,215	11-10-1992	Bosselman et al.	
	11	US-5,217,997	06-08-1993	Levere	
	12	US-5,279,833	01-18-1994	Rose	
	13	US-5,286,634	02-15-1994	Stadler et al.	
	14	US-5,399,346	03-21-1995	Anderson et al.	
	15	US-5,489,742	02-06-1996	Hammer et al.	
	16	US-5,550,316	08-27-1996	Mintz	
	17	US-5,550,024	08-27-1996	Rothschild	
	18	US-5,573,933	11-12-1996	Seamark et al.	
	19	US-5,614,396	03-25-1997	Bradley et al.	
	20	US-5,625,125	04-29-1997	Bennett et al.	
	21	US-5,641,484	06-24-1997	Hung et al.	
	22	US-5,643,567	07-01-1997	Hung et al.	
	23	US-5,646,008	07-08-1997	Thompson et al.	
	24	US-5,648,061	07-15-1997	Bernstein et al.	
	25	US-5,651,964	07-29-1997	Hung et al.	
	26	US-5,741,957	04-21-1998	Deboer et al.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 601.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/785,374
		Filing Date	2/24/2004
		First Named Inventor	Summar et al.
		Art Unit	1634
		Examiner Name	Diana B. Johannsen
		Attorney Docket Number	1242/58 CIP
Sheet	3	of	8

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	38	Ahrens et al., "Consensus statement from a Conference for the Management of Patients With Urea Cycle Disorders," Supplement to the Journal of Pediatrics, Vol. 138, No. 1, pgs. S1-S5 (January 2001).	
	39	Ananthakrishnan et al., "L-Citrulline ameliorates chronic hypoxia-induced pulmonary hypertension in newborn piglets," Am. J. Physiol. Lung Cell. Mol. Physiol., Vol. 297, pgs. L506-L511 (2009).	
	40	Ballard et al., "Inhaled nitric oxide in preterm infants undergoing mechanical ventilation," N. Engl. J. Med., Vol. 355, No. 4, pgs. 343-353 (2006).	
	41	Barr et al., "Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: Potential therapy for postoperative pulmonary hypertension," The Journal of Thoracic and Cardiovascular Surgery, Vol. 134, No. 2, pgs. 319-326 (August 2007).	
	42	Barsotti, "Measurement of ammonia in blood," The Journal Of Pediatrics, Vol. 138, pgs. S11-S20 (January 2001).	
	43	Batista da Costa, Jr. et al., "Surgical treatment of intracranial aneurysms: six-year experience in Belo Horizonte, MG, Brazil," Arq Neuro-Psiquiatr (Sao Paulo), Vol. 62, pgs. 245-249 (2004).	
	44	Batshaw et al., "Alternative pathway therapy for urea cycle disorders: Twenty years later," J. Pediatr., Vol. 138, pgs. S46-S55 (2001).	
	45	Berkenbosch et al., "Decreased synthesis and vasodilation to nitric oxide in piglets with hypoxia-induced pulmonary hypertension," Am. J. Physiol. Lung Cell. Mol. Physiol., Vol. 278, pgs. L276-L283 (2000).	
	46	Coude et al., "Inhibition of ureagenesis by valproate in rat hepatocytes. Role of N-acetylglutamate and acetyl-CoA," Biochem. J., Vol. 216, pgs. 233-236 (1983).	
	47	Dimopoulou et al., "High Incidence of Neuroendocrine Dysfunction in Long-Term Survivors of Aneurysmal Subarachnoid Hemorrhage," Stroke, Vol. 35, pgs. 2884-2889 (2004).	
	48	Flett et al., "Aneurysmal Subarachnoid Hemorrhage: Management Strategies and Clinical Outcomes in a Regional Neuroscience Center," AJNR Am. J. Neuroradiol., Vol. 26, pgs. 367-372 (2005).	
	49	Genbank Accession No. AB005600	
	50	Genbank Accession No. AH005315	
	51	Genbank Accession No. BAA24088	
	52	Genbank Accession No. M14740	
	53	Genbank Accession No. M12348	

Examiner Signature	Date Considered
---------------------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/785,374
		Filing Date	2/24/2004
		First Named Inventor	Summar et al.
		Art Unit	1634
		Examiner Name	Diana B. Johannsen
Sheet	4	of	8
		3Attorney Docket Number	1242/58 CIP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	54	Genbank Accession No. M12319	
	55	Genbank Accession No. M12320	
	56	Genbank Accession No. M12321	
	57	Genbank Accession No. M12022	
	58	Genbank Accession No. M12320	
	59	Genbank Accession No. M12324	
	60	Genbank Accession No. M12325	
	61	Genbank Accession No. M12326	
	62	Genbank Accession No. M12327	
	63	Genbank Accession No. M12328	
	64	Genbank Accession No. M12335	
	65	Genbank Accession No. M27474	
	66	Genbank Accession No. P03065	
	67	Genbank Accession No. P07258	
	68	Genbank Accession No. X67670	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known Application Number 10/785,374 Filing Date 2/24/2004 First Named Inventor Summar et al. Art Unit 1634 Examiner Name Diana B. Johannsen Attorney Docket Number 1242/58 CIP	
Sheet	5	of	8

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	69	Horiuchi et al., "Sex-Related Differences in Patients Treated Surgically for Aneurysmal Subarachnoid Hemorrhage," Neurol. Med. Chir. (Tokyo), Vol. 46, pgs. 328-332 (2006).	
	70	Interview Summary corresponding to U.S. Patent Application Serial No. 09/585,077 dated November 4, 2004.	
	71	Jobe et al., "Bronchopulmonary Dysplasia," Am. J. Respir. Crit. Care Med., Vol. 163, pgs. 1723-1729 (2001).	
	72	Kinouchi et al., "Prevention of Symptomatic Vasospasm After Aneurysmal Subarachnoid Hemorrhage by Intraoperative Cisternal Fibrinolysis Using Tissue-Type Plasminogen Activator Combined with Continuous Cisternal Drainage," Neurol. Med. Chir. (Tokyo), Vol. 141, pgs. 1143-1148 (June/July 2001).	
	73	Kivisaari et al., "MR Imaging After Aneurysmal Subarachnoid Hemorrhage and Surgery: A Long-term Follow-up Study," AJNR Am. J. Neuroradiol., Vol. 22, pgs. 1143-1148 (June/July 2001).	
	74	Leonard, J., "The nutritional management of urea cycle disorders," The Journal of Pediatrics, Vol. 138, No. 1, pgs. S40-S45 (2001).	
	75	Notice of Allowance corresponding to U.S. Patent Application Serial No. 09/323,472 (Patent No. 6,346,382) dated August 9, 2001.	
	76	Notice of Allowance corresponding to U.S. Patent Application Serial No. 09/585,077 dated October 8, 2003.	
	77	Notification of Transmittal of International Search Report or the Declaration corresponding to International Application No. PCT/US00/15079 dated August 22, 2000.	
	78	Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration corresponding to International Application No. PCT/US 09/32824 dated April 21, 2009.	
	79	Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration corresponding to International Application No. PCT/US 09/32826 dated March 25, 2009.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete If Known

Application Number	10/785,374
Filing Date	2/24/2004
First Named Inventor	Summar et al.
Art Unit	1634
Examiner Name	Diana B. Johannsen
Attorney Docket Number	1242/58 CIP

Sheet 6 of 8

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	80	Office Action corresponding to European Patent Application No. 06 005 642.1 – 2403 dated November 12, 2010.	
	81	Office Action corresponding to U.S. Patent Application Serial No. 09/989,956 dated October 18, 2006.	
	82	Office Action corresponding to U.S. Patent Application Serial No. 09/989,956 dated January 30, 2006.	
	83	Office Action corresponding to U.S. Patent Application Serial No. 09/989,956 dated July 1, 2004.	
	84	Office Action corresponding to U.S. Patent Application Serial No. 09/323,472 (Patent No. 6,346,382) dated December 20, 2000.	
	85	Office Action corresponding to U.S. Patent Application Serial No. 09/585,077 dated July 3, 2002.	
	86	Office Action corresponding to U.S. Patent Application Serial No. 12/122,117 dated April 21, 2010.	
	87	Office Action corresponding to U.S. Patent Application Serial No. 12/122,117 dated July 22, 2010.	
	88	Office Action corresponding to U.S. Patent Application Serial No. 12/364,078 dated October 21, 2010.	
	89	Office Action corresponding to U.S. Patent Application Serial No. 12/364,078 dated March 4, 2010.	
	90	Olsvik et al., "A nested PCR followed by magnetic separation of amplified fragments for detection of Escherichia coli Shiga toxin genes," Molecular and Cellular Probes, Vol. 5, pgs. 429-435 (December 1991).	
	91	Rabinstein et al., "Patterns of Cerebral Infarction in Aneurysmal Subarachnoid Hemorrhage," Stroke, Vol. 36, pgs. 992-997 (2005).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B.J.

Substitute for form 1449B/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center;">Complete if Known</th> </tr> <tr> <td style="width: 50%;">Application Number</td> <td>10/785,374</td> </tr> <tr> <td>Filing Date</td> <td>2/24/2004</td> </tr> <tr> <td>First Named Inventor</td> <td>Summar et al.</td> </tr> <tr> <td>Art Unit</td> <td>1634</td> </tr> <tr> <td>Examiner Name</td> <td>Diana B. Johannsen</td> </tr> <tr> <td>Attorney Docket Number</td> <td>1242/58 CIP</td> </tr> </table>		Complete if Known		Application Number	10/785,374	Filing Date	2/24/2004	First Named Inventor	Summar et al.	Art Unit	1634	Examiner Name	Diana B. Johannsen	Attorney Docket Number	1242/58 CIP
Complete if Known																	
Application Number	10/785,374																
Filing Date	2/24/2004																
First Named Inventor	Summar et al.																
Art Unit	1634																
Examiner Name	Diana B. Johannsen																
Attorney Docket Number	1242/58 CIP																
Sheet	7	of	8														

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cita No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	92	Ravnik et al., "Long-term Cognitive Deficits in Patients with Good Outcomes after Aneurysmal Subarachnoid Hemorrhage from Anterior Communicating Artery," Croat. Med. J., Vol. 47, pgs. 253-263 (2006).	
	93	Rubenfeld et al., "Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines," Annals of Internal Medicine, Vol. 125, pgs. 625-633 (1996).	
	94	Rubio and Grisolia, "Human Carbamoylphosphate Synthetase I," Enzyme, Vol. 26, pgs. 233-239 (1981).	
	95	Ryan, R. M., "A new look at bronchopulmonary dysplasia classification," J. Perinatology, Vol. 26, pgs. 207-209 (2006).	
	96	Saiki, R.K., "Amplification of Genomic DNA," Chapter 2 in PCR Protocols: A Guide to Methods and Applications, Innis, M.A. et al, eds., Academic Press, Inc., San Diego, pgs 13-21 (1990).	
	97	Sakowitz et al., "Relation of Cerebral Energy Metabolism and Extracellular Nitrite and Nitrate Concentrations in Patients after Aneurysmal Subarachnoid Hemorrhage," Journal of Cerebral Blood Flow and Metabolism," Vol. 21, pgs. 1067-1076 (2001).	
	98	Schreiber et al. "Inhaled nitric oxide in premature infants with respiratory distress syndrome", New England J. Med., Vol. 349, pgs. 2099-2107 (2003).	
	99	Sercombe et al., "Cerebrovascular Inflammation Following Subarachnoid Hemorrhage," Jpn. J. Pharmacol., Vol. 88, pgs. 227-249 (2002).	
	100	Singh et al., "Nutritional Management of Urea Cycle Disorders," Crit. Care Clin., Vol. 21, pgs. S27-S35, (2005).	
	101	Smith et al., "Nitric oxide precursors and congenital heart surgery: A randomized controlled trial of oral citrulline," The Journal of Thoracic and Cardiovascular Surgery, Vol. 132, No. 1, pgs. 58-65 (July 2006).	
	102	Smith et al., "Urea Cycle Disorders: Clinical Presentation Outside the Newborn Period," Crit Care Clin, Vol. 21, pgs. S9-S17 (2005).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 *Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO

(Use as many sheets as necessary)

Complete if Known

Application Number	10/785,374
Filing Date	2/24/2004
First Named Inventor	Summar et al.
Art Unit	1634
Examiner Name	Diana B. Johannsen
Attorney Docket Number	1242/58 CIP

Sheet	8	of	8
-------	---	----	---

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	103	Suarez et al., "Aneurysmal Subarachnoid Hemorrhage," N. Engl. J. Med., Vol. 354, pgs. 387-396 (2006).	
	104	Summar and Tuchman, "Proceedings of a Consensus Conference for the Management of Patients with Urea Cycle Disorders," J. Pediatr., Vol. 138, pgs. S6-S10 (2001).	
	105	Summar, M., "Current strategies for the management of neonatal urea cycle disorders," J. Pediatr., Vol. 138, pgs. S30-S39 (2001).	
	106	Takiguchi, "Transcriptional regulation of genes for ornithine cycle enzymes," Biochem J., Vol. 312, pgs. 649-659 (1995).	
	107	Thorell et al., "Optical Coherence Tomography: A New Method to Assess Aneurysm Healing," J. Neurosurg., Vol. 102, No. 2, pgs. 348-354 (2005).	
	108	van der Schaaf et al., "New Detected Aneurysms on Follow-Up Screening in Patients with Previously Clipped Intracranial Aneurysms: Comparison with DSA or CTA at the Time of SAH," Stroke, Vol. 36, pgs. 1753-1758 (2005).	
	109	Wong et al., "Use of Phenytoin and Other Anticonvulsant Prophylaxis in Patients with Aneurysmal Subarachnoid Hemorrhage Response," Stroke, Vol. 36, pg. 2532 (2005).	

Examiner Signature	/Diana B. Johannsen/
--------------------	----------------------

Date Considered	09/22/2011
-----------------	------------

This collection of information is required by 37 CFR 1.988. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is guaranteed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.B.J.